NCT00209365已完成不适用
The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit
Fraunhofer-Institute of Toxicology and Experimental Medicine2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2005年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- AMP hyperrespnsiveness
研究概览
简要总结
The aim of the study is to explore the contribution of pollen starch granules to the induced symptoms and airway inflammation in patients with allergic rhinitis and mild asthma in a controlled pollen exposure(pollen challenge room at the Fraunhofer ITEM). Starch granules are released from the pollen grains and are considered to be the allergen carriers of the pollen. The hypothesis is proposed that pollen starch granules are important in the induction of airway inflammation and airway hyperresponsiveness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Diagnostic
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Male and female subjects, aged 18-55 years. Women will be considered for inclusion if they are:
- •Not pregnant or nursing.
- •Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and have been amenorrhoeic for more than 1 year prior to the screening visit).
- •Of childbearing potential and using an appropriate method of contraception (Oral contraceptive pill or double barrier).
- •Documented history of bronchial asthma first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta2-agonist therapy by inhalation. Patients on low dose steroids will be washed out for 4 weeks.
- •FEV1 > 80% of predicted at screening.
- •They have history of allergic rhinitis to grass pollen and a positive skin prick test for Dactylus glomerata pollen at or within 12 months prior to the screening visit.
- •Documented sensitivity to AMP with a provocative concentration of AMP resulting in a 20% fall in FEV1 (PC20 AMP) of <80mg/ml at the screening visit.
- •Non smoker or smokers with a history of less than 10 pack years.
- •Able and willing to give written informed consent to take part in the study.
- •Available to complete all study measurements.
排除标准
- •• History of a respiratory tract infection and/or exacerbation of asthma within 4 weeks before the informed consent and during the study.
- •Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxic seizures.
- •Administration of oral, injectable or dermal corticosteroids within 8 weeks or intranasal and/or inhaled corticosteroids within 4 weeks of the screening visit.
- •Administration of xanthines (including theophylline, but not including caffeine), anticholinergics, cromoglycates and/or long acting beta-agonists within 1 week of the screening visit.
- •Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDS), anti-depressant drugs, anti-histamines and anti-asthma, anti-rhinitis or hay fever medication (other than short acting inhaled beta-agonists) and paracetamol (up to 1g paracetamol per day is permitted for the treatment of minor ailments e.g. headache) for 1 week prior to screening and throughout the course of the study.
- •Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis). History of MI or CVA are specific contra-indications to AHR testing
- •Known or suspected hypersensitivity or adverse reaction to AMP
- •Subject is undergoing allergen desensitisation therapy
- •There is a risk of non-compliance with study procedures
- •Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment
结局指标
主要结局
AMP hyperrespnsiveness
次要结局
- exhaled NO
- FEV1
- Rhinomanometry
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in ElderlyUpper Respiratory InfectionsCommon ColdNCT02451163Clinical Research Center Kiel GmbH247
已完成
2 期
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic RhinoconjunctivitisGrass Pollen AllergyHay FeverNCT01308021BioTech Tools S.A.202
已完成
不适用
Effect of Pollen Challenges on Dermal Symptoms in Patients With Atopic DermatitisAtopic DermatitisNCT01475994Fraunhofer-Institute of Toxicology and Experimental Medicine18
已完成
1 期
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic RhinoconjunctivitisSeasonal Allergic RhinoconjunctivitisNCT00833066BioTech Tools S.A.54
已完成
1 期
Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic RhinitisSeasonal Allergic RhinoconjunctivitisNCT00813046BioTech Tools S.A.8